{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T12:17:15Z","timestamp":1789906635749,"version":"4.0.1"},"reference-count":29,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Disease-a-Month"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.disamonth.2025.101969","type":"journal-article","created":{"date-parts":[[2025,6,26]],"date-time":"2025-06-26T07:49:13Z","timestamp":1750924153000},"page":"101969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Myasthenia gravis: Mechanisms, clinical syndromes, and diagnosis"],"prefix":"10.1016","volume":"71","author":[{"given":"Faisal","family":"Fecto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.disamonth.2025.101969_bib0001","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.3390\/jcm10112235","article-title":"Myasthenia Gravis: epidemiology, pathophysiology and clinical manifestations","volume":"10","author":"Dresser","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2025.101969_bib0002","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","article-title":"Pathogenesis of Myasthenia Gravis: update on disease types, models, and mechanisms","volume":"5","author":"Phillips","year":"2016","journal-title":"F1000Res"},{"key":"10.1016\/j.disamonth.2025.101969_bib0003","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1186\/1471-2377-10-46","article-title":"A Systematic Review of Population based Epidemiological Studies in Myasthenia Gravis","volume":"10","author":"Carr","year":"2010","journal-title":"Bmc Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0004","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1111\/j.1749-6632.1987.tb51321.x","article-title":"Clinical correlations of antibodies that bind, block, or modulate Human acetylcholine receptors in Myasthenia Gravis","volume":"505","author":"Howard","year":"1987","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.disamonth.2025.101969_bib0005","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJM197805182982004","article-title":"Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation","volume":"298","author":"Drachman","year":"1978","journal-title":"N Engl J Med"},{"key":"10.1016\/j.disamonth.2025.101969_bib0006","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/j.1365-2249.2006.03205.x","article-title":"The membrane attack pathway of complement drives pathology in passively induced experimental autoimmune myasthenia gravis in mice","volume":"146","author":"Morgan","year":"2006","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0007","doi-asserted-by":"crossref","first-page":"20783","DOI":"10.1073\/pnas.1313944110","article-title":"MuSK IgG4 autoantibodies cause myasthenia gravis by inhibiting binding between MuSK and Lrp4","volume":"110","author":"Huijbers","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.disamonth.2025.101969_bib0008","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080695","article-title":"MuSK Myasthenia Gravis IgG4 disrupts the interaction of LRP4 with MuSK but both IgG4 and IgG1-3 can disperse preformed agrin-independent AChR clusters","volume":"8","author":"Koneczny","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.disamonth.2025.101969_bib0009","article-title":"Factors affecting IgG4-mediated complement activation","volume":"14","author":"Oksam","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1212757","article-title":"Immunotherapies in MuSK-positive Myasthenia Gravis; an IgG4 antibody-mediated disease","volume":"14","author":"Vakrakou","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0011","doi-asserted-by":"crossref","first-page":"2842","DOI":"10.21037\/jtd.2018.04.95","article-title":"Myasthenia Gravis as a prognostic marker in patients with thymoma","volume":"10","author":"Cacho-Diaz","year":"2018","journal-title":"J Thorac Dis"},{"key":"10.1016\/j.disamonth.2025.101969_bib0012","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1111\/ene.14820","article-title":"Clinical characteristics and outcomes of thymoma-associated Myasthenia Gravis","volume":"28","author":"Alvarez-Velasco","year":"2021","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0013","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596981","article-title":"Myasthenia Gravis: autoantibody specificities and their role in MG management","volume":"11","author":"Lazaridis","year":"2020","journal-title":"Front Neuro"},{"key":"10.1016\/j.disamonth.2025.101969_bib0014","article-title":"Thymoma and myasthenia gravis: an examination of a paraneoplastic manifestation","volume":"15","author":"Itani","year":"2023","journal-title":"Cureus"},{"key":"10.1016\/j.disamonth.2025.101969_bib0015","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1277596","article-title":"Role of complement in Myasthenia Gravis","volume":"14","author":"San","year":"2023","journal-title":"Front Neuro"},{"key":"10.1016\/j.disamonth.2025.101969_bib0016","doi-asserted-by":"crossref","first-page":"809","DOI":"10.3389\/fimmu.2020.00809","article-title":"CD4+ T cells of Myasthenia Gravis patients are characterized by increased IL-21, IL-4, and IL-17A productions and higher presence of PD-1 and ICOS","volume":"11","author":"\u00c7ebi","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0017","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1056\/NEJMra1602678","article-title":"Myasthenia Gravis","volume":"375","author":"Gilhus","year":"2016","journal-title":"N Eng J Med"},{"key":"10.1016\/j.disamonth.2025.101969_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2020.596382","article-title":"Outcome measures in clinical trials of patients with myasthenia gravis","volume":"11","author":"Thomsen","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0019","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1212\/WNL.0b013e3181a41211","article-title":"Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals","volume":"72","author":"Alshekhlee","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101969_bib0020","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.3390\/jcm10071537","article-title":"Drugs that induce or cause deterioration of myasthenia gravis: an update","volume":"10","author":"Sheikh","year":"2021","journal-title":"J Clin Med"},{"key":"10.1016\/j.disamonth.2025.101969_bib0021","doi-asserted-by":"crossref","first-page":"634","DOI":"10.3389\/fneur.2020.00634","article-title":"Immune checkpoint inhibitor-induced myasthenia gravis","volume":"11","author":"Huang","year":"2020","journal-title":"Front Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0022","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1212\/CON.0000000000000800","article-title":"Myasthenia Gravis and congenital myasthenic syndromes","volume":"25","author":"Ciafaloni","year":"2019","journal-title":"Contin Lifelong Learn Neurol"},{"issue":"5","key":"10.1016\/j.disamonth.2025.101969_bib0023","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/WCO.0000000000001300","article-title":"Congenital myasthenic syndromes: increasingly complex","volume":"37","author":"Ramdas","year":"2024","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0024","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/S1474-4422(14)70201-7","article-title":"Congenital myasthenic syndromes: pathogenesis, diagnosis, and treatment","volume":"14","author":"Engel","year":"2015","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.disamonth.2025.101969_bib0025","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.disamonth.2025.101969_bib0026","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1212\/WNL.0000000000011124","article-title":"International consensus guidance for management of myasthenia gravis: 2020 update","volume":"96","author":"Narayanaswami","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101969_bib0027","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3949\/ccjm.90a.22017","article-title":"Myasthenia gravis: frequently asked questions","volume":"90","author":"Morren","year":"2023","journal-title":"Cleveland Clinic J Med"},{"key":"10.1016\/j.disamonth.2025.101969_bib0028","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000211166","article-title":"Risk of false acetylcholine receptor autoantibody positivity by radioimmunoprecipitation assay in clinical practice","volume":"104","author":"Zara","year":"2025","journal-title":"Neurology"},{"key":"10.1016\/j.disamonth.2025.101969_bib0029","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/mus.26985","article-title":"Clinical features of LRP4\/agrin-antibody\u2013positive Myasthenia Gravis: a multicenter study","volume":"62","author":"Rivner","year":"2020","journal-title":"Muscle Nerve"}],"container-title":["Disease-a-Month"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502925001233?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0011502925001233?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T13:10:08Z","timestamp":1754572208000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0011502925001233"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S0011502925001233"],"URL":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101969","relation":{},"ISSN":["0011-5029"],"issn-type":[{"value":"0011-5029","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Myasthenia gravis: Mechanisms, clinical syndromes, and diagnosis","name":"articletitle","label":"Article Title"},{"value":"Disease-a-Month","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.disamonth.2025.101969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"101969"}}